Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

ICD implantation for secondary prevention in patients with ventricular arrhythmia in the setting of acute cardiac ischemia and a history of myocardial infarction.

van Dijk VF, Quast ABE, Schaap J, Balt JC, Kelder JC, Wijffels MCEF, de Groot JR, Boersma LVA.

J Cardiovasc Electrophysiol. 2020 Jan 16. doi: 10.1111/jce.14357. [Epub ahead of print]

PMID:
31944462
2.

Combining left atrial appendage closure and catheter ablation for atrial fibrillation: 2-year outcomes from a multinational registry.

Phillips KP, Romanov A, Artemenko S, Folkeringa RJ, Szili-Torok T, Senatore G, Stein KM, Razali O, Gordon N, Boersma LVA.

Europace. 2019 Oct 30. pii: euz286. doi: 10.1093/europace/euz286. [Epub ahead of print]

PMID:
31665276
3.

The subcutaneous implantable cardioverter defibrillator in 2019 and beyond.

van Dijk VF, Boersma LV.

Trends Cardiovasc Med. 2019 Oct 1. pii: S1050-1738(19)30135-5. doi: 10.1016/j.tcm.2019.09.006. [Epub ahead of print] Review.

4.

PREventive left atrial appenDage resection for the predICtion of fuTure atrial fibrillation: design of the PREDICT AF study.

van den Berg NWE, Neefs J, Berger WR, Boersma LVA, van Boven WJ, van Putte BP, Kaya A, Kawasaki M, Driessen AHG, de Groot JR; PREDICT AF Investigators.

J Cardiovasc Med (Hagerstown). 2019 Nov;20(11):752-761. doi: 10.2459/JCM.0000000000000868.

PMID:
31567634
5.

Targeting Nonpulmonary Vein Sources in Persistent Atrial Fibrillation Identified by Noncontact Charge Density Mapping.

Willems S, Verma A, Betts TR, Murray S, Neuzil P, Ince H, Steven D, Sultan A, Heck PM, Hall MC, Tondo C, Pison L, Wong T, Boersma LV, Meyer C, Grace A.

Circ Arrhythm Electrophysiol. 2019 Jul;12(7):e007233. doi: 10.1161/CIRCEP.119.007233. Epub 2019 Jun 27.

PMID:
31242746
6.

Rationale and design of the PRAETORIAN-DFT trial: A prospective randomized CompArative trial of SubcutanEous ImplanTable CardiOverter-DefibrillatoR ImplANtation with and without DeFibrillation testing.

Quast ABE, Baalman SWE, Betts TR, Boersma LVA, Bonnemeier H, Boveda S, Brouwer TF, Burke MC, Delnoy PPHM, El-Chami M, Kuschyk J, Lambiase P, Marquie C, Miller MA, Smeding L, Wilde AAM, Knops RE.

Am Heart J. 2019 Aug;214:167-174. doi: 10.1016/j.ahj.2019.05.002. Epub 2019 May 16.

PMID:
31220775
7.

Left atrial appendage closure in atrial fibrillation patients with prior major bleeding or ineligible for oral anticoagulation.

Wintgens LIS, Vorselaars VMM, Klaver MN, Swaans MJ, Alipour A, Rensing BJWM, Post MC, Boersma LVA.

Neth Heart J. 2019 Dec;27(12):613-620. doi: 10.1007/s12471-019-1295-5.

8.

Thrombi outside the left atrial appendage: "small potatoes"?

Maarse M, Boersma LVA, Swaans MJ.

EuroIntervention. 2019 Jun 12;15(3):e216-e218. doi: 10.4244/EIJV15I3A39. No abstract available.

9.

Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN.

Søndergaard L, Wong YH, Reddy VY, Boersma LVA, Bergmann MW, Doshi S, Kar S, Sievert H, Wehrenberg S, Stein K, Holmes DR Jr.

JACC Cardiovasc Interv. 2019 Jun 10;12(11):1055-1063. doi: 10.1016/j.jcin.2019.04.004.

PMID:
31171282
10.

Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED): Clinical characteristics and perioperative results.

Boersma LV, El-Chami MF, Bongiorni MG, Burke MC, Knops RE, Aasbo JD, Lambiase PD, Deharo JC, Russo AM, Dinerman J, Shaik N, Barr CS, Carter N, Appl U, Brisben AJ, Stein KM, Gold MR.

Heart Rhythm. 2019 Nov;16(11):1636-1644. doi: 10.1016/j.hrthm.2019.04.048. Epub 2019 May 10.

11.

Left atrial appendage occlusion in patients older than 85 years. Safety and efficacy in the EWOLUTION registry.

Cruz-González I, Ince H, Kische S, Schmitz T, Schmidt B, Gori T, Foley D, de Potter T, Tschishow W, Vireca E, Stein K, Boersma LV.

Rev Esp Cardiol (Engl Ed). 2020 Jan;73(1):21-27. doi: 10.1016/j.rec.2019.02.008. Epub 2019 Apr 5. English, Spanish.

PMID:
30956034
12.

Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology.

Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, Gori T, Meincke F, Protopopov AV, Betts T, Mazzone P, Foley D, Grygier M, Sievert H, De Potter T, Vireca E, Stein K, Bergmann MW; following investigators and institutions participated in the EWOLUTION study.

Circ Arrhythm Electrophysiol. 2019 Apr;12(4):e006841. doi: 10.1161/CIRCEP.118.006841.

PMID:
30939908
13.

Therapy From a Novel Substernal Lead: The ASD2 Study.

Boersma LVA, Merkely B, Neuzil P, Crozier IG, Akula DN, Timmers L, Kalarus Z, Sherfesee L, DeGroot PJ, Thompson AE, Lexcen DR, Knight BP.

JACC Clin Electrophysiol. 2019 Feb;5(2):186-196. doi: 10.1016/j.jacep.2018.11.003. Epub 2018 Dec 26.

14.

Thoracoscopic vs. catheter ablation for atrial fibrillation: long-term follow-up of the FAST randomized trial.

Castellá M, Kotecha D, van Laar C, Wintgens L, Castillo Y, Kelder J, Aragon D, Nuñez M, Sandoval E, Casellas A, Mont L, van Boven WJ, Boersma LVA, van Putte BP.

Europace. 2019 May 1;21(5):746-753. doi: 10.1093/europace/euy325.

15.

Left atrial catheter ablation in patients with previously implanted left atrial appendage closure devices.

Wintgens LIS, Klaver MN, Swaans MJ, Alipour A, Balt JC, van Dijk VF, Rensing BJWM, Wijffels MCEF, Boersma LVA.

Europace. 2019 Mar 1;21(3):428-433. doi: 10.1093/europace/euy237.

PMID:
30380015
16.

Biventricular pacing after AV-node ablation for atrial fibrillation with heart failure: something old and something new, future standard, or just for the few?

Boersma LVA.

Eur Heart J. 2018 Dec 1;39(45):4009-4011. doi: 10.1093/eurheartj/ehy627. No abstract available.

PMID:
30364972
17.

Silent atrial fibrillation in patients with an implantable cardioverter defibrillator and coronary artery disease (INDICO AF) trial: study rationale and design.

Baalman SWE, Boersma LVA, Allaart CP, Meine M, Scheerder COS, de Groot JR.

Neth Heart J. 2018 Dec;26(12):628-633. doi: 10.1007/s12471-018-1185-2.

18.

Percutaneous versus thoracoscopic ablation of symptomatic paroxysmal atrial fibrillation: a randomised controlled trial - the FAST II study.

Sindby JE, Vadmann H, Lundbye-Christensen S, Riahi S, Hjortshøj S, Boersma LVA, Andreasen JJ.

J Cardiothorac Surg. 2018 Oct 3;13(1):101. doi: 10.1186/s13019-018-0792-8.

19.

[Percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation: is left atrial appendage closure an alternative for anticoagulation?]

Boersma LVA, Rensing BJWM, Wintgens LI, Klaver M, Swaans MJ.

Ned Tijdschr Geneeskd. 2018 Jun 15;162. pii: D2494. Dutch.

PMID:
30040296
20.

The Subcutaneous ICD. Ready to Conquer Everyone's Heart?

Boersma LVA.

Rev Esp Cardiol (Engl Ed). 2018 Nov;71(11):886-887. doi: 10.1016/j.rec.2018.05.018. English, Spanish. No abstract available.

PMID:
29929918
21.

A combined epicardial implantation and subsequent extraction strategy in pacemaker device infection in pacemaker-dependent patients.

van den Brink FS, van Dijk VF, Boersma LV, Wijffels MC, Gelissen J, Daeter E, Sonker U, Balt J.

Pacing Clin Electrophysiol. 2018 May 23. doi: 10.1111/pace.13382. [Epub ahead of print]

PMID:
29790185
22.

Propensity score matched comparison of subcutaneous and transvenous implantable cardioverter-defibrillator therapy in the SIMPLE and EFFORTLESS studies.

Brouwer TF, Knops RE, Kutyifa V, Barr C, Mondésert B, Boersma LVA, Lambiase PD, Wold N, Jones PW, Healey JS.

Europace. 2018 Sep 1;20(FI2):f240-f248. doi: 10.1093/europace/euy083.

PMID:
29771327
23.

Novel Extravascular Defibrillation Configuration With a Coil in the Substernal Space: The ASD Clinical Study.

Chan JYS, Lelakowski J, Murgatroyd FD, Boersma LV, Cao J, Nikolski V, Wouters G, Hall MCS.

JACC Clin Electrophysiol. 2017 Aug;3(8):905-910. doi: 10.1016/j.jacep.2016.12.026. Epub 2017 Mar 29.

24.

Incidence of pericardial effusion after left atrial appendage closure: The impact of underlying heart rhythm-Data from the EWOLUTION study.

Schmidt B, Betts TR, Sievert H, Bergmann MW, Kische S, Pokushalov E, Schmitz T, Meincke F, Mazzone P, Stein KM, Ince H, Boersma LVA.

J Cardiovasc Electrophysiol. 2018 Jul;29(7):973-978. doi: 10.1111/jce.13626. Epub 2018 May 21.

PMID:
29722469
25.

Six-year follow-up of the initial Dutch subcutaneous implantable cardioverter-defibrillator cohort: Long-term complications, replacements, and battery longevity.

Quast ABE, van Dijk VF, Yap SC, Maass AH, Boersma LVA, Theuns DA, Knops RE.

J Cardiovasc Electrophysiol. 2018 Jul;29(7):1010-1016. doi: 10.1111/jce.13498. Epub 2018 Apr 20.

PMID:
29626366
26.

Optimizing S-ICD implant technique: No pain, the true gain?

Boersma LVA.

Int J Cardiol. 2018 May 1;258:159-160. doi: 10.1016/j.ijcard.2018.02.023. No abstract available.

PMID:
29544924
27.

Thoracoscopic left atrial appendage clipping as novel treatment option for peri-device leakage.

Kougioumtzoglou AM, Smith T, Swaans MJ, Boersma LVA, van Putte BP.

Europace. 2018 Jun 1;20(6):955. doi: 10.1093/europace/eux377. No abstract available. Erratum in: Europace. 2018 Jul 1;20(7):1230.

PMID:
29342255
28.

Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy: results of the DAPT subgroup from the EWOLUTION all-comers study.

Bergmann MW, Ince H, Kische S, Schmitz T, Meincke F, Schmidt B, Foley D, Betts TR, Grygier M, Protopopov AV, Stein KM, Boersma LVA.

EuroIntervention. 2018 Apr 20;13(17):2003-2011. doi: 10.4244/EIJ-D-17-00672.

29.

Combining Watchman left atrial appendage closure and catheter ablation for atrial fibrillation: multicentre registry results of feasibility and safety during implant and 30 days follow-up.

Phillips KP, Pokushalov E, Romanov A, Artemenko S, Folkeringa RJ, Szili-Torok T, Senatore G, Stein KM, Razali O, Gordon N, Boersma LVA.

Europace. 2018 Jun 1;20(6):949-955. doi: 10.1093/europace/eux183.

30.

Do long working hours predispose to atrial fibrillation?

Mahmoodi BK, Boersma LV.

Eur Heart J. 2017 Sep 7;38(34):2629-2631. doi: 10.1093/eurheartj/ehx385. No abstract available.

PMID:
28911190
31.

Feasibility of multiplane microtransoesophageal echocardiographic guidance in structural heart disease transcatheter interventions in adults.

Nijenhuis VJ, Alipour A, Wunderlich NC, Rensing BJWM, Gijsbers G, Ten Berg JM, Suttorp MJ, Boersma LVA, van der Heyden JAS, Swaans MJ.

Neth Heart J. 2017 Dec;25(12):669-674. doi: 10.1007/s12471-017-1036-6.

32.

Dutch outcome in implantable cardioverter-defibrillator therapy (DO-IT): registry design and baseline characteristics of a prospective observational cohort study to predict appropriate indication for implantable cardioverter-defibrillator.

van Barreveld M, Dijkgraaf MGW, Hulleman M, Boersma LVA, Delnoy PPHM, Meine M, Tuinenburg AE, Theuns DAMJ, van der Voort PH, Kimman GP, Buskens E, Tijssen JPG, Bruinsma N, Verstraelen TE, Zwinderman AH, van Dessel PHFM, Wilde AAM; DO-IT investigators.

Neth Heart J. 2017 Oct;25(10):574-580. doi: 10.1007/s12471-017-1016-x.

33.

Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry.

Bergmann MW, Betts TR, Sievert H, Schmidt B, Pokushalov E, Kische S, Schmitz T, Meincke F, Stein KM, Boersma LVA, Ince H.

EuroIntervention. 2017 Sep 20;13(7):877-884. doi: 10.4244/EIJ-D-17-00042.

34.

Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial.

Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, Gori T, Meincke F, Protopopov AV, Betts T, Foley D, Sievert H, Mazzone P, De Potter T, Vireca E, Stein K, Bergmann MW; EWOLUTION Investigators.

Heart Rhythm. 2017 Sep;14(9):1302-1308. doi: 10.1016/j.hrthm.2017.05.038. Epub 2017 May 31.

35.

Effects of epicardial versus transvenous left ventricular lead placement on left ventricular function and cardiac perfusion in cardiac resynchronization therapy: A randomized clinical trial.

van Dijk VF, Fanggiday J, Balt JC, Wijffels MCEF, Daeter EJ, Kelder JC, Boersma LVA.

J Cardiovasc Electrophysiol. 2017 Aug;28(8):917-923. doi: 10.1111/jce.13242. Epub 2017 Jun 14.

PMID:
28471012
36.

Cardiac Resynchronization Therapy With Wireless Left Ventricular Endocardial Pacing: The SELECT-LV Study.

Reddy VY, Miller MA, Neuzil P, Søgaard P, Butter C, Seifert M, Delnoy PP, van Erven L, Schalji M, Boersma LVA, Riahi S.

J Am Coll Cardiol. 2017 May 2;69(17):2119-2129. doi: 10.1016/j.jacc.2017.02.059.

37.

Preliminary findings on the safety of 1.5 and 3 Tesla magnetic resonance imaging in cardiac pacemaker patients.

van Dijk VF, Delnoy PPHM, Smit JJJ, Ramdat Misier RA, Elvan A, van Es HW, Rensing BJWM, Raciti G, Boersma LVA.

J Cardiovasc Electrophysiol. 2017 Jul;28(7):806-810. doi: 10.1111/jce.13231. Epub 2017 Jun 8.

PMID:
28429537
38.

Novel stroke risk reduction in atrial fibrillation: left atrial appendage occlusion with a focus on the Watchman closure device.

Alipour A, Wintgens LI, Swaans MJ, Balt JC, Rensing BJ, Boersma LV.

Vasc Health Risk Manag. 2017 Mar 6;13:81-90. doi: 10.2147/VHRM.S89213. eCollection 2017. Review.

39.

Outpatient treatment with the wearable cardioverter defibrillator: clinical experience in two Dutch centres.

Quast AFBE, van Dijk VF, Wilde AAM, Knops RE, Boersma LVA.

Neth Heart J. 2017 May;25(5):312-317. doi: 10.1007/s12471-017-0957-4.

40.

Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication.

Boersma LV, Barr CS, Burke MC, Leon AR, Theuns DA, Herre JM, Weiss R, Kremers MS, Neuzil P, Husby MP, Carter N, Stivland TM, Gold MR; EFFORTLESS and IDE Study Investigators.

Heart Rhythm. 2017 Mar;14(3):367-375. doi: 10.1016/j.hrthm.2016.11.025. Epub 2016 Nov 24.

41.

Rotor mapping and ablation: Spinning out of control?

Boersma LV.

Heart Rhythm. 2017 Feb;14(2):198-199. doi: 10.1016/j.hrthm.2016.11.026. Epub 2016 Nov 24. No abstract available.

PMID:
27890740
42.

Atrial appendage occlusion for stroke prevention in patients with atrial fibrillation.

Swaans MJ, Boersma LV.

Heart. 2016 Dec 15;102(24):1943-1944. doi: 10.1136/heartjnl-2016-310198. Epub 2016 Sep 13. No abstract available.

PMID:
27625372
43.

Percutaneous left atrial appendage closure devices: safety, efficacy, and clinical utility.

Swaans MJ, Wintgens LI, Alipour A, Rensing BJ, Boersma LV.

Med Devices (Auckl). 2016 Sep 2;9:309-16. doi: 10.2147/MDER.S65492. eCollection 2016. Review.

44.

Multielectrode Pulmonary Vein Isolation Versus Single Tip Wide Area Catheter Ablation for Paroxysmal Atrial Fibrillation: A Multinational Multicenter Randomized Clinical Trial.

Boersma LV, van der Voort P, Debruyne P, Dekker L, Simmers T, Rossenbacker T, Balt J, Wijffels M, Degreef Y.

Circ Arrhythm Electrophysiol. 2016 Apr;9(4):e003151. doi: 10.1161/CIRCEP.115.003151.

PMID:
27071830
45.

Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry.

Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, Pokushalov E, Kische S, Schmitz T, Stein KM, Bergmann MW; EWOLUTION investigators.

Eur Heart J. 2016 Aug;37(31):2465-74. doi: 10.1093/eurheartj/ehv730. Epub 2016 Jan 27.

46.

EWOLUTION: Design of a registry to evaluate real-world clinical outcomes in patients with AF and high stroke risk-treated with the WATCHMAN left atrial appendage closure technology.

Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, Stein KM, Bergmann MW.

Catheter Cardiovasc Interv. 2016 Sep;88(3):460-5. doi: 10.1002/ccd.26358. Epub 2015 Dec 31.

PMID:
26719158
47.

Detailed characterization of familial idiopathic ventricular fibrillation linked to the DPP6 locus.

Ten Sande JN, Postema PG, Boekholdt SM, Tan HL, van der Heijden JF, de Groot NM, Volders PG, Zeppenfeld K, Boersma LV, Nannenberg EA, Christiaans I, Wilde AA.

Heart Rhythm. 2016 Apr;13(4):905-12. doi: 10.1016/j.hrthm.2015.12.006. Epub 2015 Dec 8.

PMID:
26681609
48.

Ablation for Atrial Fibrillation Combined With Left Atrial Appendage Closure.

Alipour A, Swaans MJ, van Dijk VF, Balt JC, Post MC, Bosschaert MAR, Rensing BJ, Reddy VY, Boersma LVA.

JACC Clin Electrophysiol. 2015 Dec;1(6):486-495. doi: 10.1016/j.jacep.2015.07.009. Epub 2015 Oct 22.

49.

Longevity of the Subcutaneous Implantable Defibrillator: Long-Term Follow-Up of the European Regulatory Trial Cohort.

Theuns DA, Crozier IG, Barr CS, Hood MA, Cappato R, Knops RE, Maass AH, Boersma LV, Jordaens L.

Circ Arrhythm Electrophysiol. 2015 Oct;8(5):1159-63. doi: 10.1161/CIRCEP.115.002953. Epub 2015 Jul 6.

PMID:
26148819
50.

Early performance of a miniaturized leadless cardiac pacemaker: the Micra Transcatheter Pacing Study.

Ritter P, Duray GZ, Steinwender C, Soejima K, Omar R, Mont L, Boersma LV, Knops RE, Chinitz L, Zhang S, Narasimhan C, Hummel J, Lloyd M, Simmers TA, Voigt A, Laager V, Stromberg K, Bonner MD, Sheldon TJ, Reynolds D; Micra Transcatheter Pacing Study Group.

Eur Heart J. 2015 Oct 1;36(37):2510-9. doi: 10.1093/eurheartj/ehv214. Epub 2015 Jun 4.

Supplemental Content

Loading ...
Support Center